当前位置：   首页 > 需求大厅

 >  生产研发 

单人中标 赏金分配： $ 30,000 截止日期：2015年1月5日 已有提案：104件 发布时间：14年11月3日 已选0个，还需要1个。 具体要求：研究人员需要一种理论和数学模型来描述已知药物分子和药物性质来预测在水溶媒中药片的溶出过程。这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2015年1月5日下午11时59分（美国东部时间）收到，逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时，必须将其独有的知识产权（IP）的权利转让给举办方。 2.这个悬赏任务是必须寻找一种理论和数学模型来描述已知药物分子和药物性质来预测在水溶媒中药片的溶出过程。而这种药物的晶形、分子结构、活性和非活性成份的重量比、粒径、水溶液的PH等等都是已知并且固定的。 3、投稿在此网站：Multi-Scale Modeling of Tablet Dissolution | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933558   [更多]

本公司需要拉米夫定和齐多夫定的大生产工艺，有意向者请联系   [更多]

　　要求 　　1.不得侵犯他人专利，如有侵犯，提供者承担损失 　　2.要求有详细技术参数，不能只是一个合成路线 　　3.要求生产路线，成品率不得比现有公开合成方法低 　　4.要求为中试生产工艺   [更多]

基因治疗的概念出现在几十年前,当研究人员推测,人类疾病可以通过精确使用一种技术引入外来DNA来解决遗传缺陷和疾病症状。近年来，基因治疗的进步已经涉足治疗遗传疾病，癌症，神经退行性疾病等各领域。遗传性疾病如色素性视网膜炎等少数眼部疾病的基因也可以如此治疗。公司征集一种在人类眼部组织定性和定量(半)测量体内基因表达的方法。 具体如下https://www.innocentive.com/ar/challenge/9933643 The concept of gene therapy arose decades ago, when researchers postulated that human diseases could be treated by using a technique to introduce foreign DNA to correct genetic defects and disease phenotypes. In recent years, advances in gene therapy have been documented in the treatment of genetic disorders, cancer, and neurodegenerative diseases. Inherited diseases such as retinitis pigmentosa are among a handful of ocular diseases that are amenable to gene therapy. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933643 Challenge Overview The number of clinical trials for gene therapy to treat ocular disorders is on the rise. Inherited diseases such as retinitis pigmentosa among others are thought to be good candidates for targeted treatment. Currently, there is no method in humans to determine the level or geographic location of transgene expression following administration of gene therapy for diseases of the eye, specifically the retina. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 20, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a   [更多]

　　富马酸酮替芬原料工艺，要求工艺成熟，标准EP   [更多]

求五水头孢唑林钠原料药合成工艺，有的请回复！   [更多]

肝脏疾病是一种由病毒或有毒物连续侵害造成肝脏晚期纤维化的慢性疾病。目前，我们的治疗方法很有限，寻找治疗方法的大多数临床试验都失败了，部分原因是由于缺乏预测肝脏疾病发展的生物标志物。公司需要寻找一种新的生物标志物，对提高疾病的可控性会有很大的帮助，定期监测生物标志物也可以促进临床试验治疗药物的进一步发展。 具体可以查看https://www.innocentive.com/ar/challenge/9933671 Challenge Overview Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive   [更多]

单人中标 赏金分配： $ 50,000 截止日期：计2015年1月12日 已有提案：57 件 发布时间：2014年11月6日 已选0个，还需要1个。 具体要求： 与年龄相关的黄斑变性（AMD）是造成50岁以上人的视力丧失的主要原因。黄斑变性会造成视网膜的中央点损害，并模糊，最后会使一个或两个眼睛发展到失明。虽然AMD已有少量模型存在，但并没有充分阐明疾病的病理，而且也不适合于彻底深入地筛选和开发药物。年龄相关性黄斑变性（AMD）被认为是由遗传和环境因素来触发一种复杂而且异质性疾病。正如它的名字所示的，随着年龄的增长AMD发病率增加，据估计，在美国，大约有800万55周岁以上的人具有中期或后期的疾病。 AMD出现的第一症状为黄斑色素的改变和被称为玻璃疣的视网膜下沉积物。疾病进一步发展可能导致视网膜色素上皮（RPE）细胞和光感受器细胞或新血管的血管渗透，出血和疤痕。光感受器细胞和视网膜色素上皮细胞之间的相互作用对于正常的视力功能是必不可少的。这一悬赏只需要一个书面建议。 以下几条信息必须同时满足: 1. 必须在2015年1月12日下午11时59分（美国东部时间）收到，逾期的投标概不受理。只需要提案人一个书面建议提交。解决方领取奖金的同时，必须将其独有的知识产权（IP）的权利转让给举办方。 2.这个悬赏任务是必须寻找一种新的，临床前模型，描述光感受器细胞和视网膜色素上皮细胞之间的相互作用，在长期生理分化中对视力的影响，以方便对最近出现的新兴疗法进行疗效评价。 3、在这个网站投稿：Preclinical Models of Age-Related Macular Degeneration | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933641   [更多]

甲基多巴  METHYL DOPA  CAS 555-30-6求购：原料药 甲基多巴的商业化生产工艺，非专利网的文献。有实际完整生产工艺的可以详谈！甲基多巴是一种抗高血压药，为白色或类白色结晶性粉末；无臭。其主要是在中枢转化成甲基去甲肾上腺素。甲基去甲肾上腺素是一种很强的中枢α2受体激动药。用于中、重度或恶性高血压，还有镇静、降低眼压作用。   [更多]

求购 苯磺顺阿曲库铵 原料药 商业化生产工艺！Q2736068151苯磺顺阿曲库铵(cisatracurium besylate)是最新一代肌松剂，广泛应用于气管 插管、肝肾功能障碍、心血管手术等领域。苯磺酸阿曲库铵有4个手性中心，10个同分异构体，分子中含有4个手性中心，其中2个为手性碳，2个为手性氮，顺苯磺阿曲库铵为1R,1'R,2R,2'R异构体。我方需求顺苯磺阿曲库铵大生产合成工艺，要求整个工艺有较好的选择性，反应的收率和产品的纯度较高。我司需要商业化生产工艺而不是 专利网文献，需求真实有效，可提供者可私聊！   [更多]